Venetoclax has durable clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.
A combination of the FLT3 kinase inhibitor quizartinib with 5-azacitidine or low-dose cytarabine is active in patients with FLT3-ITD mutated myeloid leukemias, according to a new study.
A new study has found that there are significant gaps in participation among people aged 75 and older in clinical trials of hematologic malignancies when considered against the incidence of these malignancies in this age group.
CAR T cells targeting CD19 can be effective at treating relapsed/refractory diffuse large B-cell lymphoma or follicular lymphoma, with high rates of durable remission.
History of Epstein-Barr virus or immunosuppression did not affect outcomes for patients with diffuse large B-cell lymphoma.
This video highlights results of a study that examined predictors for unplanned hospital readmissions in patients with hematologic malignancies.
In those with DLBCL, Burkitt lymphoma, and Hodgkin lymphoma, cure is often achieved. Furthermore, in the salvage setting, whether auto-HCT or allo-HCT is used, the same appears to be true. A great deal of progress has been made in the treatment of lymphoma in patients with HIV infection, but more remains to be done before outcomes are comparable to those of the general population.
In this slide show we highlight some of the top news on hematologic cancers in 2017, including effective therapies for pediatric hematologic malignancies, a variety of FDA approvals, new discoveries in myeloma, and more.
Hospice use occurred more frequently among Medicare beneficiaries with acute and chronic leukemias who were transfusion dependent, according to the results of a study presented at the ASH Annual Meeting.
A long-term analysis of the FOLL05 trial found favorable outcomes at 8 years in advanced-stage follicular lymphoma patients treated with three different rituximab/chemotherapy combinations.